• Treosulfan, a low toxicity alkylating agent, can be used effectively as part of conditioning for HSCT in children with CGD.
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Treosulfan containing conditioning regimens can be used safely in HSCT for children with CGD and high-risk clinical features, achieving excellent survival with high myeloid chimerism. Further studies are needed to compare with other regimens and evaluate the long-term outcome particularly on fertility.
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INTRODUCTION
Chronic granulomatous disease (CGD) is a primary immunodeficiency (PID) in which mutations in genes encoding one of the five subunits of the enzyme nicotinamide adenine dinucleotide phosphate oxidase (NADPH-O) lead to failure of microbiocidial oxygen metabolite generation 1 . This causes impaired microbial killing, which leads to severe life threatening bacterial and fungal infections. Additionally, impairment in the regulation and termination of pro-inflammatory cytokine-mediated signals cause granuloma formation and inflammation 1 . Despite rigorous antibiotic and antifungal prophylaxis and treatment of inflammatory complications, ongoing medical problems are common in paediatric and adult patients, with a significant disease-related mortality [2] [3] [4] [5] .
Haematopoietic stem cell transplantation (HSCT) can cure CGD with resolution of infections and inflammatory complications [5] [6] [7] . In addition, growth and quality of life are improved in transplanted patients compared to those treated conservatively 4, 8 .
Historically high-risk patients with ongoing infectious or active inflammatory complications at HSCT had considerable transplant-related mortality (TRM) up to 38% 9,10 . Efforts to reduce the toxicity of the conditioning regimen were complicated by high rates of autologous reconstitution and graft-versus-host disease (GvHD) 10, 11 .
Recently, there has been increasing interest in the use of reduced-intensity conditioning (RIC) regimens for patients with PID 12 and specifically for those with CGD 13 . These regimens cause minimal toxicity and achieve high rates of cure even in patients with underlying infections and/or organ dysfunction.
Treosulfan, a bifunctional alkylating agent with myeloablative and immunosuppressive effects, has been increasingly used as one of the main conditioning agents for HSCT for children with malignant and non-malignant disorders in some European and US centres
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From [14] [15] [16] [17] [18] . It has a low-toxicity profile, the most commonly reported acute toxicities being skin including nappy rash, diarrhoea, mucositis and hepatic toxicity; however these are generally mild and importantly veno-occlusive disease (VOD) is very rare 19 . Long term effects are not well-documented due to the relatively recent introduction of the drug for conditioning for HSCT.
The purpose of this retrospective analysis was to determine the outcome of Treosulfanbased conditioning for patients with CGD. We report a multicentre paediatric series of 70 patients with CGD who underwent HSCT using Treosulfan as the main agent for conditioning.
PATIENTS, MATERIALS AND METHODS

DATA COLLECTION Centres identified through the Inborn Errors Working Party (IEWP) of the European
Society for Blood and Marrow Transplantation (EBMT) who had performed HSCT for CGD using a Treosulfan based conditioning regimen were asked to participate in the retrospective study.
Data were submitted for 70 patients from 16 centres in nine countries worldwide (UK, Germany, Belgium, Poland, Czech Republic, Italy, Israel, USA, Australia) following a questionnaire distributed by the IEWP of the EBMT.
The following data were collected: risk features prior to HSCT, additional conditioning agents to Treosulfan, donor type, stem cell source and number, toxicity -presence of skin toxicity, neurotoxicity or VOD-, platelet and neutrophil engraftment, occurrence of acute GvHD (aGvHD) following Glucksberg criteria and/or chronic GvHD 20 (cGvHD), donor chimerism with lineage specific chimerism CD3, CD19/CD20 and CD15/CD33 when available, viral reactivation (CMV, EBV, adenovirus, HHV6), other HSCT complications, length of follow-up and outcome. For the analysis of the parameters platelet and neutrophil engraftment, occurrence of GvHD and donor chimerism, one patient was excluded as he died on day +1. The 8 patients receiving a second procedure were included in the analysis of GvHD as none of them developed either aGvHD or cGvHD after the first transplant.
All patients or their guardians gave written consent according to local centre and EBMT guidelines.
PATIENT CHARACTERISTICS
Sixty-six of the 70 patients were male. Two patients with long histories of recurrent infection were 19 years old (232 months) at the time of HSCT, the rest were under 18 years of age with a median of 9 years (107 months, IQR 46-232). Fifty-six had Xlinked CGD and 11 were reported as having autosomal recessive (AR) disease: 4 CYBA, 4 NCF1 and 1 NCF2. For the other 2 patients, even after being extensively investigated, no mutation was found; however, based on the family history -females affected-and the Dihydrorhodamine (DHR) pattern, X linked inheritance was excluded.
For 3 patients this information was not available.
All except 6 patients had ongoing or previous radiologically and microbiologically proven infection or autoinflammation defined as high-risk criteria pre-HSCT. Amongst the 64 (91%) patients who had these high-risk criteria, 34 patients had more than one.
The most frequently reported complication was infection in 52 patients, with previous microbiologically proven Aspergillus in 12, followed by colitis in 35, chronic lung disease in 15 and failure to thrive in 10 patients. Other significant symptoms reported in 10 patients were bladder inflammation, previous splenectomy, McLeod phenotype, pericardial effusion, thymus abscesses, allergic bronchopulmonary aspergillosis (ABPA), recurrent haemophagocytic lymphohistiocytosis and brain lesions with the 
RESULTS
SURVIVAL
Sixty-four patients are alive with a median follow up of 34 (IQR 13-102) months, giving an overall survival of 91.4% (Figure 1 ). The 2-year probability of survival was 90.48%, (95% CI 79.86 -95.65). There was no significant difference in overall survival between those who received an URD graft and those who received a MRD transplant (92.9% vs 85.7% p=0.255).
Of the 6 deaths due to transplant related mortality, only 2 occurred in the first 100 days post-HSCT highlighting the low toxicity of the regimens (Table 2) .
One patient with severe multisystem inflammatory disease and previous Aspergillus infection developed multi-organ failure during conditioning and died on day +1. The remaining 5 deaths were associated with severe GvHD, severe infection, or both ( Table   2 ). 
TOXICITY
There were no serious toxicities except for the expected chemotherapy related myelosuppression. Nine patients had limited skin toxicity, including perianal ulceration, pigment changes, and occasional peeling. Two had CNS toxicity other than tremor related to cyclosporin A (1 idiopathic epilepsy, 1 proximal myopathy).
No VOD occurred, even in the patients who had undergone previous HSCT.
ENGRAFTMENT
Platelet engraftment (first day of platelet >20 x 10 9 /l for three consecutive days)
occurred at a median of 16 days (IQR 13-50) and neutrophil engraftment (first day of neutrophils >0.5 x 10 9 /l for three consecutive days) at 17 days (IQR 15-35) post-HSCT.
One patient died on Day+1 and one patient who died at 10 months post-HSCT did not achieve platelet engraftment despite 100% donor chimerism.
VIRAL REACTIVATIONS
Thirty-four patients (48.5%) had viral reactivation, 11 of them having more than one virus isolated in the blood. CMV was present in 22, EBV in 14, Adenovirus in 8 and HHV6 in 4 patients. Disseminated adenovirus infection contributed to the death in 2 patients and influenza pneumonitis in 1. Amongst these 34 patients, 29 had received previous serotherapy, either with alemtuzumab (n=19) or ATG (n=10).
GRAFT-VERSUS-HOST DISEASE
Twenty-seven patients (39%) developed aGvHD grade I-II and the cumulative incidence of GvHD grade III-IV was 12% (8 patients). The incidence of grade III-IV GvHD was 7.6% for the MRD recipients (n=1) and 12.5% for the URD recipients (n=7). This difference was not statistically significant (p=0.082).
Nine patients (13%) developed cGvHD: in 4 this was limited to the skin, in 3 it was extensive in the skin, joints and muscle and in 2 it was extensive in the skin, gut and
liver. In 5 patients cGvHD has resolved and patients are off immunosuppression, 1 is on a weaning dose of immunosuppressive treatment with no symptoms, 1 has ongoing symptoms in spite of treatment and 2 with extensive disease of skin, gut and liver died.
There was an unexpectedly higher cumulative incidence of cGvHD in the MRD group, 30.7% (n=4), compared to the URD group, 16% (n=9), (p=0.035). Three of these MRD recipients did not receive any serotherapy.
Amongst the URD recipients, there was no statistically significant difference in There was a statistically significant difference in incidence of grade I-II aGvHD comparing serotherapy use versus none (ATG n=11 vs alemtuzumab n= 16 vs nil n=0, p=0.002); this difference was not significant depending on the serotherapy agent (ATG vs nil p<0.0001; alemtuzumab vs nil p = 0.006; ATG vs alemtuzumab p=0.158).
The patients who received serotherapy and developed grade III-IV aGvHD or cGvHD were n=5 and n=6 respectively compared to those who did not receive any, n=3 for each type of GvHD, but the differences were not statistically significant (p=0.19 for grade III-IV aGvHD and p=0.305 for cGvHD).
COMPLICATIONS
Other significant complications reported were: autoimmune haemolytic anaemia (2), immune pancytopenia (1), thrombotic microangiopathy (1), multifocal avascular necrosis (1), Guillain Barre syndrome (1) and disseminated Aspergillus infection (1).
EVENTS AND CHIMERISM
Eight patients required second procedures resulting in an EFS of 81.4% at the median follow up of 34 months (IQR 13-102) ( Figure 2 ). The 2-year probability of EFS was 81.03%, (95% CI 68.79 -88.85%). All these patients had received a total dose of Treosulfan of 42 g/m² but one, who received 36 g/m².
There was no significant difference between URD and MRD recipients (80.4% vs 85.7%, p = 0.490). Moreover, we found there was no difference in incidence of secondary graft failure with progressive decreasing chimerism in those patients with (4/22) or without (9/48) CMV reactivation (p=0.9).
Second procedures included 2 boosts from the original donor without further conditioning; one of the patients died after developing severe extensive GvHD and disseminated adenovirus infection. Three received donor lymphocyte infusions (DLI) and 5 underwent a 2 nd HSCT (of whom 2 had received DLI) ( Table 3 ).
In 64 patients for whom data were available, last reported donor myeloid chimerism was >95% in 51 (80%) of patients and T lymphoid chimerism was >95% in 48 (75%) of patients ( Figure 3 ). The remaining 6 patients were excluded for the following reasons:
the patient who died on day +1, one of the patients who received an additional procedure for decreasing chimerism, whose chimerism pre-transplant was not available, and 4 who had whole blood chimerism below 100% but split chimerism was not reported. For these 4 patients, the whole blood chimerism was 89%, 74%, 54% and 39%
respectively.
The patients did not have a neutrophil oxidative function performed routinely; myeloid chimerism > 50% can be considered enough for recovery of neutrophil function in the CGD.
CONDITIONING AGENTS AND SEROTHERAPY
All the centres used Treosulfan as the main condition agent, but otherwise the regimens were quite heterogeneous; 15 patients had additional thiotepa, but there was no significant difference in terms of graft failure -n=2-(p=0.794), higher percentage of myeloid chimerism -n=12-(p=0.3146) or deaths -n=0-(p=0. 3289) compared to those who did not receive thiotepa (n=6, n=34 and n=6 respectively).
Fifty-seven patients received either ATG or alemtuzumab compared to 13 who did not receive any serotherapy.
No significant differences were found in deaths -n=4 in the serotherapy group compared to n=2 in non-serotherapy (p=0.470) or graft failures -n=8 versus n=0 respectively (p=0.140).
GENETIC TYPE
As stated above, there were 56 patients with X linked CGD and 11 patients with autosomal recessive CGD. For 3 patients the information was not available, so they have been excluded from this analysis. 51 of the X linked CGD patients and 10 of the AR had high-risk features pre-transplant. All the deceased patients had X linked CGD, as well as 7 of the 8 who needed a second procedure. There is a 100% survival and 91% EFS in the AR group compared to a 89.3% and a 87.5% respectively in the X linked group; these differences were not significant when analysed (survival p = 0.255, EFS p=0.75).
DISCUSSION
Without HSCT patients with CGD face life-threatening infections and other complications that lead to shortened lifespan and diminished life quality [2] [3] [4] [5] . While
HSCT is the only curative therapy, patients often have significant co-morbidities, particularly moulds and other infections which may contribute to TRM. Over the past 1 4 10 years there have been multiple reports suggesting that Treosulfan-based regimens were associated with reduced incidence of TRM when used for conditioning patients with hematologic malignancies or other life-threatening disorders including CGD 14,16-18 .
However we report the largest series to date of children with CGD who underwent allogeneic HSCT using Treosulfan-based conditioning.
With a median follow up of 34 months, the overall survival was excellent at 91.4% with an EFS of 81.4% in a high-risk group of patients in this study (nearly all of the patients had significant pre-HSCT risk factors including infection(s) and/or inflammation). In addition, there were no differences in overall survival or EFS between matched and mismatched donor grafts or the addition of thiotepa to the conditioning regimen.
Due to the retrospective nature of the study, no toxicity scale was used, but in the reported cases the toxicity was minimal; in particular, no VOD occurred even in patients receiving a second transplant. Two patients had neurotoxicity and nine had mild skin toxicity which resolved.
Some comparisons can be made with the results shown by Gungor et al 13 , who published the largest prospective study of a RIC regimen for HSCT for this disease in a cohort of paediatric and adult patients (median age 12.7 years, IQR 6.8-17.3). Using a sub-myeloablative total dose of busulfan, and at a median follow-up of 21 months, the overall survival was 93% and EFS 89%, with very promising results in terms of low toxicity, sustained chimerism and therefore, recovery of neutrophil function.
Eight patients in our cohort experienced secondary graft failure, one of whom died. The remaining patients had stable donor chimerism in myeloid and lymphoid lineages at last follow up, compatible with cure of the underlying disease. We did not find a relationship between graft failure and CMV reactivation as was recently reported 22 . In the study published by Gungor et al 13 , 3 patients experienced graft-failure and received In this series 5 patients had previous graft failure after conditioning with fludarabine and melphalan (n=1) and busulfan (n=4).
There were 6 deaths in our cohort, 2 in the first 100 days, and all but one were associated either with severe GvHD, severe viral infection or both. We cannot draw any conclusions regarding differences in age, other conditioning agents used, or donor type.
Although the overall incidence of aGVHD was high at 51%, the incidence of severe acute grade III-IV GvHD was low at 8% compared to 16% in a report of children with malignancy using Treosulfan based conditioning 17 . cGVHD developed in 9 patients (13%), but 6 of whom are now free of symptoms. GvHD was not associated with use of serotherapy, or the donor source. Further work needs to be done to determine optimal timing and dosing of serotherapy to minimise the risks of GvHD and viral reactivation.
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In Gungor´s 13 study, grade III-IV aGvHD was only 4% and cGvHD was present in 4 of 56 patients (7%), 3 of them of paediatric age. Viral reactivation was reported in almost half of the patients but resolved with appropriate therapy, and contributed to death in two patients. This highlights the importance of monitoring and pre-emptive therapy for viral reactivation in patients receiving serotherapy.
These results show that HSCT using a Treosulfan-based conditioning regimen is a safe treatment option in paediatric patients with CGD, even in those with high-risk clinical features pre-HSCT or those with no HLA-identical family donor as it has been previously recommended. We observed high curative rates and minimal toxicity with excellent survival, comparable to low intensity conditioning regimens 24 . A third of the patients in this study had additional agents to Treosulfan, fludarabine and serotherapy
and so further studies are needed to establish a consistent approach. The other main study using RIC published by Gungor et al 13 is prospective and includes mainly an adult population with a smaller proportion of X linked CGD patients than our cohort (60% versus 83%). Our results suggest that X linked CGD patients have a somewhat higher mortality and less successful transplants than those with AR-CGD although this did not reach statistical significance. This could contribute to the small differences in survival, transplant success and GvHD between the two studies. Prospective studies will be required comparing Treosulfan with low dose busulfan based regimens, but will need to have lengthy follow-up in order to determine any differences in chimerism and longterm toxicity. Further studies are also needed to evaluate the pharmacokinetics of 
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